Home » Merck KGaA Drops Oral MS Drug Cladribine Following FDA Meeting
Merck KGaA Drops Oral MS Drug Cladribine Following FDA Meeting
Merck KGaA is abandoning its approval efforts for its oral multiple sclerosis (MS) drug cladribine after a meeting with the FDA, and it is pulling the drug from markets where it is already approved.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May